Compare IBEX & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | CLLS |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.7M | 384.3M |
| IPO Year | 2017 | 2014 |
| Metric | IBEX | CLLS |
|---|---|---|
| Price | $28.80 | $4.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $35.00 | $8.33 |
| AVG Volume (30 Days) | ★ 110.8K | 33.9K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.26 | N/A |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $558,273,000.00 | N/A |
| Revenue This Year | $14.13 | N/A |
| Revenue Next Year | $5.68 | $0.62 |
| P/E Ratio | $17.40 | ★ N/A |
| Revenue Growth | ★ 9.77 | N/A |
| 52 Week Low | $23.40 | $1.33 |
| 52 Week High | $42.99 | $5.48 |
| Indicator | IBEX | CLLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.42 | 59.57 |
| Support Level | $28.26 | $3.25 |
| Resistance Level | $30.27 | $4.48 |
| Average True Range (ATR) | 0.86 | 0.21 |
| MACD | 0.29 | 0.09 |
| Stochastic Oscillator | 61.41 | 68.36 |
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.